Arima Hidetoshi, Motoyama Keiichi, Higashi Taishi, Fukushima Satoshi, Ihn Hironobu
Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University.
Program for Leading Graduate Schools "HIGO Program", Kumamoto University.
Yakugaku Zasshi. 2018;138(4):509-515. doi: 10.1248/yakushi.17-00201-4.
Atopic dermatitis (AD) is a chronic skin disease characterized by inflammation, pruritus, and eczematous lesions. Recently, sacran, a new polysaccharide isolated from cyanobacterium Aphanothece sacrum (Sur.) OKADA discovered by Suringar in the 19th century, has received considerable attention as a novel biomaterial. Previously, it was reported that sacran exhibits potent anti-inflammatory effects for skin diseases produced by various stimulants with optimum effective concentrations at 0.01% (w/v) and 0.05% (w/v) in rats and mice. Importantly, we demonstrated clinically that almost all of the average scores for AD symptoms in patient treated with sacran solutions were improved. In AD model mice, sacran treatment markedly down-regulated inflammatory cytokine and chemokine mRNA levels compared with non-treated controls. Furthermore, sacran solution significantly suppressed inflammation response in RAW264.7 cells. In RBL-2H3 cells, the sacran solution significantly lowered degranulation. Taken together, our studies suggest sacran may have the potential to improve AD through functional recovery of skin barrier and anti-inflammatory effects.
特应性皮炎（AD）是一种以炎症、瘙痒和湿疹样皮损为特征的慢性皮肤病。最近，Sacran，一种从19世纪由苏林加发现的蓝藻阿氏浮丝藻（Sur.）冈田中分离出的新型多糖，作为一种新型生物材料受到了广泛关注。此前有报道称，Sacran对由各种刺激物引起的皮肤疾病具有强大的抗炎作用，在大鼠和小鼠中的最佳有效浓度为0.01%（w/v）和0.05%（w/v）。重要的是，我们在临床上证明，用Sacran溶液治疗的患者中，几乎所有AD症状的平均评分都有所改善。在AD模型小鼠中，与未治疗的对照组相比，Sacran治疗显著下调了炎性细胞因子和趋化因子的mRNA水平。此外，Sacran溶液显著抑制了RAW264.7细胞中的炎症反应。在RBL-2H3细胞中，Sacran溶液显著降低了脱颗粒作用。综上所述，我们的研究表明Sacran可能具有通过恢复皮肤屏障功能和抗炎作用来改善AD的潜力。
